Neuro-Biotech Corp. & Auric Pharma Science Announce Completion of Buy Out Offer

KAZAN, Russian Federation, April 1 /PRNewswire/ - Neuro-Biotech Corp. (PinkSheets: MRES.pk - News) (OTCQB: MRES) and Auric Pharma Science have accepted all terms and conditions and successfully completed all due diligence requirements. Both companies have agreed to complete the agreement on Tuesday April 5 at its new corporate head office in Kazan, Russian Federation.

Mr. Boris Oleknovich, CEO and President of Neuro-Biotech Corp. commented: "Merging these two incredible companies into one, can only lead to great things, combining sales, research & development, distribution channels and great scientific minds will make us a force to be reckoned with. We would like to thank our shareholders for their loyalty and to assure them that they will greatly benefit and profit from our success."

"Mr. Oleknovich will remain President, I will assume the position of CEO, together we will build a giant, We plan to open manufacturing/production and distribution facilities in North America in the near future." stated Mr. Norman Hathaway, President and CEO of Auric Pharma Science.

For more information on Neuro-Biotech Corp or to contact a company representative, please visit: www.neuro-biotechcorp.com.

FORWARD LOOKING STATEMENTS

This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

SOURCE Neuro-Biotech Corp.